ID: ALA4092694

Max Phase: Preclinical

Molecular Formula: C25H21F3N4O4

Molecular Weight: 498.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(Nc1ccc(-c2ccc(C(=O)N3CCC[C@H]3C(=O)O)nc2)cc1)Nc1cccc(C(F)(F)F)c1

Standard InChI:  InChI=1S/C25H21F3N4O4/c26-25(27,28)17-3-1-4-19(13-17)31-24(36)30-18-9-6-15(7-10-18)16-8-11-20(29-14-16)22(33)32-12-2-5-21(32)23(34)35/h1,3-4,6-11,13-14,21H,2,5,12H2,(H,34,35)(H2,30,31,36)/t21-/m0/s1

Standard InChI Key:  HLIOKEKNYKPXNX-NRFANRHFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 498.46

Molecular Weight (Monoisotopic): 498.1515

AlogP: 5.10

#Rotatable Bonds: 5

Polar Surface Area: 111.63

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.48

CX Basic pKa: 1.61

CX LogP: 4.05

CX LogD: 0.82

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.45

Np Likeness Score: -1.44

References

1. Yan J, Wang G, Dang X, Guo B, Chen W, Wang T, Zeng L, Wang H, Hu Y..  (2017)  Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.,  25  (17): [PMID:28739155] [10.1016/j.bmc.2017.07.007]

Source

Source(1):

• Scientific Literature